Renalert
Renalert: Real-time kidney monitoring for early detection of acute injury, analyzing urine output, blood pressure, and oxygenation.
Founded
2016Renalert: Real-time kidney monitoring for early detection of acute injury, analyzing urine output, blood pressure, and oxygenation.
Renalert, founded in Baltimore, is dedicated to preventing deaths from Acute Kidney Injury (AKI) through its innovative real-time monitoring system. The company's core mission is to provide early detection of AKI by analyzing a patient’s urine output, blood pressure, and oxygenation status. This proactive approach aims to address the high mortality rate associated with AKI, which surpasses that of several major diseases combined. Renalert's market focus includes hospitals and healthcare providers seeking advanced solutions for patient monitoring and kidney health management.
Notable affiliations include Johns Hopkins University, which supports Renalert's research and development efforts. The company has garnered attention for its significant contributions to healthcare technology, particularly in the early detection and management of kidney-related conditions. Renalert's impact is evident in its potential to save lives by enabling timely medical interventions, thereby reducing the mortality rate associated with AKI.
Companies similar to Renalert include RenalGuard Solutions, Nephrosant, Rejuvenate Kidney Transplant Solutions and Kantum Pharma.
Renalert was founded in 2016.
Renalert's headquarters is located in Baltimore, MD, US.
Renalert's most recent funding round was for $25k (USD) in September 2019.
As of Sep 28, 2019, Renalert has disclosed funding of $175k (USD). Undisclosed round amounts are excluded.
Renalert has 1 employee as of Feb 4, 2024.
Kantum Pharma
